Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Deferred Taxes (2024 - 2026)

Indivior Pharmaceuticals has reported Deferred Taxes over the past 3 years, most recently at $27.0 million for Q1 2026.

  • For Q1 2026, Deferred Taxes rose 1450.0% year-over-year to $27.0 million; the TTM value through Mar 2026 reached -$17.0 million, down 950.0%, while the annual FY2025 figure was -$46.0 million, 757.14% down from the prior year.
  • Deferred Taxes for Q1 2026 was $27.0 million at Indivior Pharmaceuticals, up from -$38.0 million in the prior quarter.
  • Over five years, Deferred Taxes peaked at $37.0 million in Q4 2024 and troughed at -$38.0 million in Q4 2025.
  • A 3-year average of -$1.3 million and a median of -$2.0 million in 2025 define the central range for Deferred Taxes.
  • Biggest five-year swings in Deferred Taxes: plummeted 202.7% in 2025 and later soared 1450.0% in 2026.
  • Year by year, Deferred Taxes stood at $37.0 million in 2024, then plummeted by 202.7% to -$38.0 million in 2025, then surged by 171.05% to $27.0 million in 2026.
  • Business Quant data shows Deferred Taxes for INDV at $27.0 million in Q1 2026, -$38.0 million in Q4 2025, and -$15.0 million in Q3 2025.